{"id":85007,"date":"2018-11-22T08:22:22","date_gmt":"2018-11-22T16:22:22","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2018\/11\/dual-action-antibody-might-improve-immunotherapy-outcomes"},"modified":"2018-11-22T08:22:22","modified_gmt":"2018-11-22T16:22:22","slug":"dual-action-antibody-might-improve-immunotherapy-outcomes","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2018\/11\/dual-action-antibody-might-improve-immunotherapy-outcomes","title":{"rendered":"Dual-Action Antibody Might Improve Immunotherapy Outcomes"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/dual-action-antibody-might-improve-immunotherapy-outcomes.jpg\"><\/a><\/p>\n<p>In a study published in the journal <em> Immunology<\/em>, Southampton University researchers have shown that a new antibody that they have engineered is able to combine two different anticancer approaches: depleting regulatory T cells and activating killer T cells [1].<\/p>\n<blockquote><p><b>Abstract<\/b><\/p>\n<p>The costimulatory receptor 4-1BB is expressed on activated immune cells, including activated T cells. Antibodies targeting 4-1BB enhance the proliferation and survival of antigen-stimulated T cells in vitro and promote CD8 T cell-dependent anti-tumor immunity in pre-clinical cancer models. We found that T regulatory (Treg) cells infiltrating human or murine tumors expressed high amounts of 4-1BB. Intra-tumoral Treg cells were preferentially depleted by anti-4-1BB mAbs in vivo. Anti-4-1BB mAbs also promoted effector T cell agonism to promote tumor rejection. These distinct mechanisms were competitive and dependent on antibody isotype and FcgR availability. Administration of anti-4-1BB IgG2a, which preferentially depletes Treg cells, followed by either agonistic anti-4-1BB IgG1 or anti-PD-1 mAb augmented anti-tumor responses in multiple solid tumor models.<\/p><\/blockquote>\n<p><!-- Link: <a href=\"https:\/\/www.leafscience.org\/dual-action-antibody-might-improve-immunotherapy-outcomes\/\">https:\/\/www.leafscience.org\/dual-action-antibody-might-impro...-outcomes\/<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a study published in the journal Immunology, Southampton University researchers have shown that a new antibody that they have engineered is able to combine two different anticancer approaches: depleting regulatory T cells and activating killer T cells [1]. Abstract The costimulatory receptor 4-1BB is expressed on activated immune cells, including activated T cells. Antibodies [\u2026]<\/p>\n","protected":false},"author":418,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1902,11],"tags":[],"class_list":["post-85007","post","type-post","status-publish","format-standard","hentry","category-bioengineering","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/85007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/418"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=85007"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/85007\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=85007"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=85007"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=85007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}